Drug Profile
Research programme: diabetes therapy - STIL BioTechnologies
Alternative Names: SB 25; SB 29Latest Information Update: 26 Jan 2007
Price :
$50
*
At a glance
- Originator STIL BioTechnologies
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 11 Jul 2003 Preclinical trials in Diabetes mellitus in Israel (unspecified route)